Stocktoria
Invivyd, Inc. IVVD
Invivyd, Inc. (IVVD) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $53.4M at a -98.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.77 |
| Retained earnings / assets | -3.447 |
| EBIT / assets | -0.201 |
| Equity / liabilities | 6.834 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IVVD | Invivyd, Inc. | 2/9 | -0.36 | — | +110.5% |
| PLX | Protalix BioTherapeutics, Inc. | 2/9 | -11.01 | — | -1.2% |
| CSBR | CHAMPIONS ONCOLOGY, INC. | 5/9 | -7.27 | — | +4.4% |
| FENC | FENNEC PHARMACEUTICALS INC. | — | -4.88 | — | -6.1% |
| CHRS | Coherus Oncology, Inc. | 4/9 | — | 1.4 | +59.8% |
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
About Invivyd, Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
FAQ
Is IVVD financially healthy?
Invivyd, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IVVD pay a dividend?
No, Invivyd, Inc. does not currently pay a dividend.
How profitable is IVVD?
In FY2025, Invivyd, Inc. had a net margin of -98.2% and a return on equity of -21.7%.
What is the analyst price target for IVVD?
The average Wall-Street price target for Invivyd, Inc. is $10.00, about 1266.1% above the recent price, from 3 analysts (consensus: strong buy).
Is IVVD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Invivyd, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.